Filed: June 29, 2016

UNITED S	STATES PATENT AND TRADEMARK OFFICE
BEFORE	THE PATENT TRIAL AND APPEAL BOARD
	MYLAN PHARMACEUTICALS INC. Petitioner, v.
	ASTRAZENECA AB Patent Owner.
	Patent No. 6,774,122


PETITION FOR INTER PARTES REVIEW **OF U.S. PATENT NO. 6,774,122** 

## **TABLE OF CONTENTS**


I.	INT	RODU	JCTIO	N	1	
II.	MA	NDAT	ORY	NOTICES	2	
	A.	Real Parties-In-Interest (37 C.F.R. § 42.8(b)(1))				
	B.	Related Matters (37 C.F.R. § 42.8(b)(2))				
	C.	Identification of Counsel (37 C.F.R. § 42.8(b)(3)) and Service Information (37 C.F.R. § 42.8(b)(4))				
	D.	Service Information (37 C.F.R. § 42.8(b)(4))				
III.	GRO	DUND	S FOR	R STANDING AND PROCEDURAL STATEMENT	4	
IV.				ON OF CHALLENGE AND STATEMENT OF THE EF REQUESTED	4	
V.	THE	RESHO	OLD R	EQUIREMENT FOR INTER PARTES REVIEW	5	
VI.				F REASONS FOR THE RELIEF REQUESTED		
	A.	Summary of the Argument5				
	B.	Background on Breast Cancer and Its Treatment Options8				
	C. Background of U.S. Patent No. 6,774,122 ("the '122 patent")				10	
		1.	The	'122 Patent	10	
		2.	The	Prosecution of the '122 Patent	12	
	D.	The Person of Ordinary Skill in the Art				
	E.	Clai	Claim Construction			
	F. Patents and Printed Publications Relied On In This Petit			d Printed Publications Relied On In This Petition	18	
		1.	McI	Leskey (Ex. 1005)	19	
		2.		vell 1996 (Ex. 1006)		
		3.	Prio	r Art Informing the Knowledge of the POSA	21	
			a.	Fulvestrant Was Well Known As a Breast Cancer Treatment	22	
			b.	Oily Vehicles Were Used for Intramuscular Injections to Achieve Long-Acting Efficacy	24	
			c.	Conventional Excipients and Standard Formulation Principles Allowed Routine Formulation of	20	
				Intramuscular Injections.	∠ð	



			(i) The Profile of Conventional Excipients	28
			(ii) Standard Formulation Principles	31
G.	Petit	tioner's	s Obviousness Positions.	32
	1.	The	Law of Obviousness	32
	2.	The	Prior Art Renders the Claims Obvious	33
Н.			Claims 1–9 Were Unpatentable As Obvious Over	36
	1.	Inde	pendent Claim 1 Was Obvious over McLeskey	36
		a.	McLeskey Disclosed the Exact Formulation Recited in Claim 1.	37
		b.	The Art Disclosed Treatment of a Malignant Disease of the Breast With Fulvestrant	39
		c.	The Art Disclosed Intramuscular Injection of Oily Fulvestrant Formulations.	40
		d.	The Blood Plasma Concentration Recited in Claim 1 Is a Statement of Intended Use	41
			(i) To the Extent It Is Given Patentable Weight, Clar 1's Recitation of Blood Plasma Concentration Was Disclosed in the Art.	
		e.	McLeskey's Formulation Did Not Result in Unexpectedly Improved Solubility	42
	2.	Inde	pendent Claim 5 Was Obvious over McLeskey	44
	3.	Dependent Claims 2 and 9 Were Obvious over McLeskey.		
	4.	_	endent Claims 3 and 4 Were Obvious over eskey	45
		a.	The Statements of Intended Result in Claims 3 and 4 Are Not Entitled to Patentable Weight	45
		b.	To the Extent They Are Given Patentable Weight, the Recitations of Claims 3 and 4 Were Obvious	46
	5.	Depe	endent Claims 6–8 Were Obvious over McLeskey	46
I.			Claims 1–9 Were Unpatentable As Obvious over	17



	1.	_	oendent Claim I Was Obvious Over Howell 1996 in of McLeskey	47
	2.	_	pendent Claim 5 Was Obvious Over Howell 1996 in of McLeskey	51
	3.		andent Claims 2 and 9 Were Obvious Over Howell in View of McLeskey	51
	4.		endent Claims 3 and 4 Were Obvious over Howell in View of McLeskey	52
	5.	-	endent Claim 6 Was Obvious Over Howell 1996 in of McLeskey	52
	6.		endent Claim 7 Was Obvious Over Howell 1996 in of McLeskey	53
	7.		endent Claim 8 Was Obvious Over Howell 1996 in of McLeskey	53
J.	-		dary Considerations Fail to Overcome the Showing ness	54
	1.	Faslo	odex Sales Do Not Save the '122 Patent	54
		a.	There is No Nexus Between the Claims and Secondary Considerations of Nonobviousness	54
		b.	Any Commercial Success of Faslodex Is Attributable to AstraZeneca's Extensive Marketing Efforts	57
	2.	The (	Claimed Methods Produced No Unexpected Results	57
	3.	The '	122 Patent Satisfied No Long-Felt but Unmet Need	58
	4.	Copy	ring Is Irrelevant	59



### **LIST OF EXHIBITS**

Exhibit	Description
1001	U.S. Patent No. 6,774,122
1002	File History For U.S. Patent No. 6,774,122
1003	Expert Declaration of Dr. Laird Forrest, Ph.D.
1004	Expert Declaration of Dr. Leslie Oleksowicz, M.D.
1005	McLeskey <i>et al.</i> , "Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors," 4 CLIN. CANCER RESEARCH 697–711 (1998) ("McLeskey")
1006	Howell <i>et al.</i> , "Pharmacokinetics, pharmacological and antitumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer," 74 Brit. J. Cancer 300–08 (1996) ("Howell 1996")
1007	EP 0 346 014 (Dukes), published 12/13/1989 ("Dukes 1989")
1008	Wakeling et al., "A Potent Specific Pure Antiestrogen with Clinical Potential," 51 CANCER RESEARCH 3867–3873 (1991) ("Wakeling 1991")
1009	Alan E. Wakeling & Jean Bowler, "ICI 182,780: A New Antioestrogen with Clinical Potential," 43 J. STEROID BIOCHEM. MOLEC. BIOL. 173–177 (1992) ("Wakeling 1992")
1010	Spiegel & Noseworthy, "Use of Nonaqueous Solvents in Parenteral Products," 52 J. PHARM. SCI. 917–927 (1963) ("Spiegel & Noseworthy")
1011	Order, AstraZeneca Pharmaceuticals LP v. Sandoz Inc., No. 14–03547 (D.N.J. July 29, 2015), ECF No. 102
1012	A. Howell, "Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer," 345 LANCET 29–30 (1995) ("Howell 1995")
1013	O'Regan et al., "Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth," 90 J. NAT'L CANCER INST. 1552–1558 (1998) ("O'Regan 1998")



# DOCKET A L A R M

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

#### **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

#### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

